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1. Introduction 
The presence of a lipase of hepatic origin in post- 
heparin plasma of experimental nimals has been 
confirmed by several investigators [1-6]. An enzyme 
with similar characteristics has also been found in 
humans [7-9]. This enzyme hydrolyzes triglycerides, 
phospholipids and acylCoA thiolesters [4,9] and has 
been shown to be a transacylase [10]. Hepatic lipase 
clearly differs from lipoprotein lipase of extrahepatic 
origin in its co-factor, equirement and immunological 
reactivity. Also, it is not inhibited by high ionic 
strength in the assay medium [5,7,11,12]. 
One of the characteristics of lipoprotein lipase is 
that it needs for full activity a VLDL-apoprotein, 
apoC-II. This has been demonstrated forpurified 
lipoprotein lipase from adipose tissue [14], heart [15], 
postheparin plasma [4] and milk [16]. A recent study 
with bovine milk lipoprotein lipase indicates, that 
depending on the substrate concentration a d the 
presence of apoC-lI in the assay medium, also apoC-I 
and apoC-III can stimulate fatty acid liberation [17]. 
We now report, that low concentrations of serum 
activate purified human postheparin plasma hepatic 
lipase. The C-apoproteins from VLDL did not cause 
this stimulation, but all of them suppressed the 
enzymatic activity. 
2. Material and methods 
2.1. Enzyme assay 
Triglyceride hydrolase was assayed using glyceryl- 
[t4C]triolein emulsified in the presence of 5% gum 
arabic as substrate [15]. Unless otherwise stated, 
assays were performed in the absence of serum and in 
a medium containing 0.1 M NaC1. 
2.2. Enzyme purification 
Hepatic lipase and lipoprotein lipase were purified 
from human postheparin plasma essentially as 
described [12], using: (a) formation of an enzyme- 
substrate complex followed by delipidation, (b) 
affinity chromatography of the solubilized prepara- 
tion on heparin-Sepharose and (c) chromatography 
on calcium phosphate gel. The specific activities of 
the final preparations were approx. 1100 and 1800 
,umol fatty acid liberated/mg protein/h, for hepatic 
lipase and lipoprotein lipase, respectively. 
2.3. Purification of  the C-apoproteins from human 
VLDL 
The C-apoproteins from human VLDL [18] were 
purified from delipidated preparations [19] as 
described by Herbert et al. [20]. They were shown 
to be pure by polyacrylamide g l electrophoresis 
[20] and by amino acid analysis [21]. 
Abbreviations: VLDL: very low density lipoproteins; apoC-I, 
apoC-11 and apoC-llI: apoproteins from very low density 
lipoproteins having carboxyl terminal mino acid serine, 
glutamic acid and alanine, respectively [13]. 
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3. Results and discussion 
The activity of purified human postheparin plasma 
hepatic lipase was measured as a function of serum 
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Fig. 1. Effect of serum on the activity of human postheparin 
plasma hepatic lipase. Effect on enzyme obtained from 
heparin-Sepharose affinity chromatography, before calcium 
phosphate gel treatment (o- -o)  and after calcium phosphate 
gel (o--o). The amount of serum in the assay medium is 
indicated on the abscissa. 
concentration i the assay medium, fig.1. A stimula- 
tion at low concentrations of serum is seen, whereas 
higher concentrations cause inhibition. This stimula- 
tion was evident also in lipase preparations before 
calcium phosphate gel chromatography, fig. 1. 
To study, if the serum stimulation was due to any 
of the C-apoproteins from VLDL, the activity of 
hepatic lipase was recorded in the presence of varying 
amounts of apoC-I, C-II and C-Ill in the assay medium 
(fig.2). They all inhibited the enzymatic activity. The 
inhibition caused by apoC-II and C-Ill was linear, 
while apoC-I was giving a sigmoidal inhibition curve. 
Thus the stimulation of hepatic lipase does not seem 
to be due to the VLDL-C-apoproteins. The identity 
of the stimulating serum factor remains uncertain, 
but it is of interest, that pre-heparin plasma causes a 
shift in the pH-optimum of the hepatic lipase [22]. 
We then added varying amounts of human VLDL 
to the standard assay medium and determined the 
activity of purified hepatic lipase and lipoprotein 
lipase (fig.3). Addition of VLDL suppressed the 
hydrolysis of [14C]triolein by both enzymes. The 
two enzymes differ in that hepatic lipase is inhibited 
by 55%, whereas lipoprotein lipase is inhibited by 
84%. Whether this inhibition is due to suppression by 
VLDL of enzymatic activities or whether this lipo- 
protein is a preferred substrate, needs further study. 
A growing interest has been focused on the role 
of lipases in lipoprotein metabolism. Although results 
obtained from in vitro studies have shown that apo- 
protein C-II plays a major role in the activation of 
lipoprotein lipase, far less is known about the role 
of other C-apoproteins. The function of the hepatic 
lipase and its relationship to apoproteins i still an 
open question. We now report that the hepatic lipase 
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Fig.2. Effect of C-apoproteins from human VLDL on the activity of human postheparin plasma hepatic lipase. (Left) Effect of 
apoC-l. (Middle) Effect of apoC-lI. (Right) Effect of apoC-IIl. The amount of apoprotein added to the assay medium is indicated 
on the abscissa. 
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Fig.3. Effect of addition of human VLDL to the assay 
medium. Enzyme activity was determined from the amount 
of ~4C-fatty acid liberated. The values are corrected for the 
isotope dilution due to the addition of VLDL-triglyceride, 
amounts indicated on the abscissa. Hepatic lipase (e--e) and 
lipoprotein lipase (o--o). 
in vitro is strongly inhibited by apoC-I, C-II and C-III. 
If intact chylomicron and VLDL triglycerides are 
preferentially hydrolyzed by lipoprotein lipase, as 
has been suggested [23,24] and not by hepatic 
lipase, the effects of the C-apoproteins on the activi- 
ties of the two triglyceride lipases could be meaning- 
ful in vivo. 
The C-apoproteins of chylomicrons and VLDL 
would inhibit the hepatic lipase and thus protect 
their triglyceride from hydrolysis by this enzyme. 
However, these lipoproteins rich in the lipoprotein 
lipase activator apoC-II, would be a good substrate 
for lipoprotein lipase in extrahepatic tissues. Follow- 
ing hydrolysis of the triglycerides of these lipopro- 
teins, remnant particles are formed [25-27] .  These 
remnants contain less C-apoproteins than the intact: 
lipoproteins [25], at least part of them being trans- 
ferred to the high density lipoproteins [28]. If hepa- 
tic lipase is involved in the removal of remnants from 
plasma, as has been suggested [29], the low concen- 
tration of C-apoprotein i  remnants might direct the 
activity of hepatic lipase towards remnant rather than 
chylomicron and VLDL triglyceride. The findings by 
Redgrave and by Noel et al. further strenghten this 
concept, they observed a rapid removal of remnant 
lipid by liver, whereas intact chylomicrons were 
taken up to a limited extent [25,30]. 
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